Insight into the different treatment options to reduce the risk of stroke in AF patients

Treatments to Reduce the Risk of Stroke in AF

Oral Anticoagulants

The most common treatment for managing AF-related stroke risk is the use of anticoagulants, such as warfarin (Coumadin®) and novel oral anticoagulants (NOACs).

Warfarin and NOACs effectively reduce the risk of cardioembolic stroke, however they are not well tolerated by some patients and carry a risk for bleeding complications.

The limits of oral anticoagulants include:

  • Risk of bleeding
  • High rate of discontinuation (at 2 years, 50% of patients on VKA and 30% on NOAC treatment)1
  • Interactions with certain foods and medications (warfarin)
  • Frequent blood tests and dose adjustment (warfarin)
Illustration of heart with WATCHMAN Device

WATCHMAN implant procedure

The WATCHMAN device offers a breakthrough approach to reduce the risk of stroke. Most blood clots in people with AF develop in the left atrial appendage (LAA).

WATCHMAN acts as a barrier to keep these blood clots from escaping the LAA, going into the bloodstream, blocking a blood vessel, and causing a stroke.

Learn more about a permanent solution designed to reduce the risk of stroke.

Innovative One-Time Solution

1. Martinez et al. Thromb Haemost 2015;114: In press. 

CAUTION: The law restricts these devices to sale by our on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Information for the use only in countries with applicable health authority product registrations. Information contained herein is for distribution outside the U.S., Japan and France.